Journals / İzmir Atatürk Eğitim Hastanesi Tıp Dergisi / 2008 / Cilt: 46 - Sayı: 4

The assesment of the endometrial abnormalities in postmenopausal asymptomatic women whit breast canser receiving tamoxifen using transvaginal ultrasonography and endometrial sampling

Tamoksifen kullanan postmenopozal semptomatik meme kanserli hastalarda transvaginal ultrasonografi ve endometrial biyopsi ile endometrial değişikliklerin değeerlendirilmesi

Pages
163–166
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The increasingspesifity and decreasingsensitivity of Transvaginal ultrasonography research were found correleted increasing endometrial thickness in asymptomatic postmenopausal women with breast canser receiving tamoxifen .

📌 3 Key Takeaways

🎯
Objective & Hypothesis:he assesment of the endometrial abnormalities in postmenopausal asymotomatic women with breast canser receiving tamoxifenusing transvaginal ultrasonographyand endometrial sampling.
📊
Key Findings & Data:Between march 2004 to february 2006 the asymptomatic postmenopausal women with breast canser receiving tamoxifenobserved at the Oncology and General Surgery Departments in İzmir Atatürk Educational and Research Hospital and counsulting to 2nd ObstetricsandGynecology Clinic for endometrial assesmentwere investigated with Transvaginal ultrasonography.
💡
Conclusion & Impact:The increasingspesifity and decreasingsensitivity of Transvaginal ultrasonography research were found correleted increasing endometrial thickness in asymptomatic postmenopausal women with breast canser receiving tamoxifen .
🔬Design:Research Article
📍Scope:2004 Verileri
⚙️Variables:Domain Parameters

Abstract

he assesment of the endometrial abnormalities in postmenopausal asymotomatic women with breast canser receiving tamoxifenusing transvaginal ultrasonographyand endometrial sampling. Between march 2004 to february 2006 the asymptomatic postmenopausal women with breast canser receiving tamoxifenobserved at the Oncology and General Surgery Departments in İzmir Atatürk Educational and Research Hospital and counsulting to 2nd ObstetricsandGynecology Clinic for endometrial assesmentwere investigated with Transvaginal ultrasonography. The sensitivity and specifty of endometrial thickness estimated with Transvaginal ultrasonographyindicating endometrial abnormalitieswerefound 98.2% and 8.9 % when endometrial thickness was 5mm, 36.8% and 88.0% when 15 mm ,12.9% and 98.9 % when 25.5mm. The increasingspesifity and decreasingsensitivity of Transvaginal ultrasonography research were found correleted increasing endometrial thickness in asymptomatic postmenopausal women with breast canser receiving tamoxifen .

Özet

Tamoksifen kullanan postmenapozal asemptomatik meme kanserli hastalarda transvaginal ultrasonografi ve endometrial biyopsi ile endometrial transvajinalultrasonografi,endometrial değişikliklerin değerlendirilmesi amaçlandı.Mart 2004 ile Şubat 2006 tarihleri arasında İzmir Atatürk Eğitim ve Araştırma Hastanesi Genel Cerrahi ve Onkoloji bölümlerince takip edilen, ikinci kadın doğum kliniğine endometrial değerlendirmeiçin gönderilen Tamoksifen tedavisi alan postmenopozal asemptomatik meme kanserli hastalar Transvajinal ultrasonografi ile incelemeye alındı. TVUS ile ölçülen endometrial kalınlığın endometrial patolojiyi göstermedeki sensitivite ve spesifisitedeğerleri endometrial kalınlık 5 mm iken % 98.2 ve % 8.9, 15 mm iken %36.8 ve %88.0, 25.5 mm iken %12.9 ve %98.9 olarak bulundu. Tamoksifen kullanan asemptomatik postmenapozal meme kanserli hastalarda endometrial kalınlıktaki artışla birlikte Transvajinal ultrasonografi çalışmalarının spesifitesinde dereceli artış olurken sensivitesinde ise dereceli azalma tespit edildi.

🔖

Cite This Article

GÜNDOĞDU, F., SOYLU, F., YILMAZ, Ş., ELVEREN, H. B., ŞENTÜRK, E. (2022). The assesment of the endometrial abnormalities in postmenopausal asymptomatic women whit breast canser receiving tamoxifen using transvaginal ultrasonography and endometrial sampling. İzmir Atatürk Eğitim Hastanesi Tıp Dergisi, Cilt: 46 - Sayı: 4, 163–166. https://ajindex.com/articles/557510

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials—Early Breast Cancer Trialists' Collaborative Group. Lancet 351:14511467, 1998
  2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 365:1687-1717, 2005
  3. Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh, Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet ii (1987), pp. 171-175
  4. B. Fisher, J. Dignam, N. Wilmark, A. DeCellis, B. Emir, L. Wickerham et al., Tamoxifen and chemotherapy for lymph node negative, estrogen receptor positive breast cancer. J. Natl. Cancer Inst 88 (1996), pp. 1529-1542. 5.Early Breast Cancer Trialists' Collaborative Group, Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998), pp. 1451-1467
  5. Althuis MD, Sexton M, Langenberg P et al. Surveillance for uterine abnormalities in tamoxifen-treated breast carcinoma survivors.Acommunity-based study. Cancer 2000; 89: 800 - 10
  6. Cohen I, Rosen DJ, Shapira J et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic postmenopausal breast cancer patients. Gynecol Oncol 1994; 52: 185 - 90
  7. Decensi A, Fontana V, Bruno S, Gustavino C, Gatteschi B, Costa A. Effect of tamoxifen on endometrial proliferation. J Clin Oncol 1996; 14: 434 - 40
  8. Deligdisch L, Kalir T, Cohen CJ, Latour M, Bouedec G, Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 2000; 78: 181- 6
  9. Franchi M, Ghezzi F, Donadello N, Zanaboni F, Bertetta P, Bolis P. Endometrial thickness in tamoxifen-treated patients: an independent predictor of endometrial disease. Obstet Gynecol 1999; 93: 1004 - 8
  10. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993; 81: 660 - 4
  11. Mourits MJE, DeVries EGE, Willemse PHB, TenHoor KA, Hollema H, VanderZee AGJ. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 2001; 97: 855 – 66
  12. Schwartz LB, Rutkowski N, Horan C, Nachtigall LE, Snyder J, Goldstein ST. Use of transvaginal ultrasonography to monitor the effects of tamox